Rivfloza™ (nedosiran) – New orphan drug approval
September 29, 2023 - Novo Nordisk announced the FDA approval of Rivfloza (nedosiran), to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2.
Top